.svg)
Esketamine
As a part of our persistent, relentless approach to help our patients suffering from treatment resistant depression (TRD). Esketamine nasal spray has been licensed by the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK as a treatment for moderate to severe treatment resistant depression that is also referred to as “difficult to treat depression”.
Referral Options
We accept referrals via the following routes. Once your referral has been processed and accepted, you will be contacted by phone or letter to book your appointment.
Private
Self-referral
Telephone 0800 844 5257
Email private@optimisehcg.co.uk
Other referral (from a private healthcare provider)
Referral should be sent to private@optimisehcg.co.uk
Screening
Esketamine is indicated for adults with Treatment-Resistant Major Depressive Disorder who have not responded to at least two different antidepressant treatments within a current moderate-to-severe depressive episode.
A chargeable assessment and screening appointment will be required to assess your eligibility for treatment.
Treatment
Stage 1
Weeks 1 - 4
Two Treatments per week - 90-120 minutes per treatment
Stage 2
Weeks 5-8
One Treatment per week - 90-120 minutes per treatment
Stage 3
Weeks 9-12
One Treatment per week OR one treatment every 2 weeks - 90-120 minutes per treatment
Stage 4
Week 13+
This will be discussed with your Consultant to assess the frequency of maintenance treatment.
All treatments are supervised by our healthcare professionals.
Patients must not drive following treatment for 24 hours.